In a report released today, Michael Ulz from Morgan Stanley upgraded Ionis Pharmaceuticals to a Buy, with a price target of $62.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Michael Ulz has given his Buy rating due to a combination of factors that highlight the strong performance and future potential of Ionis Pharmaceuticals. The company’s second quarter of 2025 exceeded expectations, particularly with the impressive launch of Tryngolza, which outperformed initial sales forecasts. This success underscores the management’s capability in commercial execution and boosts confidence in the company’s strategic direction.
Furthermore, Ulz notes the upcoming catalysts that could drive further growth, including the anticipated Phase 3 data releases for severe hypertriglyceridemia (SHTG) and other key developments in 2026. The favorable feedback from key opinion leaders regarding the pending Phase 3 CORE/CORE2 data also strengthens the outlook for Ionis. These elements combined have led to an upgraded rating to Overweight and an increased price target, reflecting a positive long-term view on the stock.
In another report released today, Needham also maintained a Buy rating on the stock with a $55.00 price target.
Based on the recent corporate insider activity of 55 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of IONS in relation to earlier this year.